You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 293 No. 18, May 11, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (13)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •HIV/AIDS
 •Alert me on articles by topic

Temporal Trends in Early Clinical Manifestations of Perinatal HIV Infection in a Population-Based Cohort

David R. Berk, MD; Meira S. Falkovitz-Halpern, PhD; David W. Hill, MPH; Catherine Albin, MD, PhD; Antonio Arrieta, MD; Jane M. Bork, MD; Deborah Cohan, MD, MPH; Bjorn Nilson, MD; Ann Petru, MD; Juan Ruiz, MD, MPH; Peggy Sue Weintrub, MD; Wanda Wenman, MD; Yvonne A. Maldonado, MD; for the California Pediatric HIV Study Group

JAMA. 2005;293:2221-2231.

Context  The effect of early antiretroviral therapy (ART) on the early progression of perinatal human immunodeficiency virus (HIV) infection is not well defined.

Objective  To examine early disease progression and survival in a population-based cohort with perinatal HIV infection in relation to year of birth and use of ART.

Design, Setting, and Patients  Retrospective study of temporal trends in early progression of perinatal HIV infection among 205 HIV-infected children in Northern California born between January 1, 1988, and December 31, 2001, and followed up through age 3 years.

Main Outcome Measures  Prevalence of and age at progression to a first US Centers for Disease Control and Prevention category C diagnosis relative to year of birth, type of ART, and age at initiation of therapy.

Results  Of 205 children, 134 (65%) received ART and/or Pneumocystis jiroveci pneumonia prophylaxis. By age 3 years, 81 (40%) progressed to a category C diagnosis, 41 (51%) of whom died. Untreated children were significantly more likely to progress to a category C diagnosis (62% [44/71] untreated vs 28% [37/134] treated children, P<.001); none of 23 infants who received triple ART progressed to category C. However, even without triple ART, very early mono/dual ART (by age 2 months vs 3-4 months) was associated with delayed and decreased progression to category C (P = .02). Of 33 children born between January 1, 1996, and December 31, 2001, only 7 (21%) progressed to category C (P = .02 compared with 1988-1995), 6 of 7 of whom received no therapy. More recent year of birth and more advanced therapy were associated with improved survival.

Conclusions  This population-based cohort demonstrated decreased early HIV progression and improved survival at age 3 years, associated with more advanced therapy. Although limited by small sample size, the findings suggest that very early treatment, even without triple ART, was associated with improved outcome.


Author Affiliations: Department of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, Calif (Drs Berk, Falkovitz-Halpern, and Maldonado and Mr Hill); Department of Pediatrics, Santa Clara Valley Medical Center, San Jose, Calif (Dr Albin); Children's Hospital of Orange County, Orange, Calif (Dr Arrieta); Loma Linda University Children’s Hospital, Loma Linda, Calif (Dr Bork); University of California, San Francisco and Bay Area Perinatal AIDS Center/San Francisco General Hospital (Dr Cohan); Specialty Services, University Medical Center, Fresno, Calif (Dr Nilson); Pediatric Infectious Diseases, Children’s Hospital & Research Center at Oakland (Dr Petru); California Department of Health Services, Office of AIDS, Sacramento (Dr Ruiz); University of California at San Francisco (Dr Weintrub); and Pediatric Infectious Diseases, University of California Davis, Sacramento (Dr Wenman).


RELATED ARTICLES

Antiretroviral Treatment in Pediatric HIV Infection in the United States: From Clinical Trials to Clinical Practice
Susan Brogly, Paige Williams, George R. Seage, III, James M. Oleske, Russell Van Dyke, Kenneth McIntosh, and for the PACTG 219C Team
JAMA. 2005;293(18):2213-2220.
ABSTRACT | FULL TEXT  

Balancing the Upside and Downside of Antiretroviral Therapy in Children
Ram Yogev
JAMA. 2005;293(18):2272-2274.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Trends in Bacteremia in the Pre- and Post-Highly Active Antiretroviral Therapy Era Among HIV-Infected Children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004)
Kapogiannis et al.
Pediatrics 2008;121:e1229-e1239.
ABSTRACT | FULL TEXT  

Early Triple Therapy vs Mono or Dual Therapy for Children With Perinatal HIV Infection
Chiappini et al.
JAMA 2006;295:626-628.
FULL TEXT  

ART for Perinatal HIV Infection Reduces Disease Progression
JWatch Women's Health 2005;2005:10-10.
FULL TEXT  

Early Diagnosis and Treatment of Pediatric HIV Infection Improves Outcomes
AIDS Clin Care 2005;2005:2-2.
FULL TEXT  

Progress in Treatment of Pediatric HIV Infection
JWatch Infect. Diseases 2005;2005:2-2.
FULL TEXT  

Balancing the Upside and Downside of Antiretroviral Therapy in Children
Yogev
JAMA 2005;293:2272-2274.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.